These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7549900)

  • 1. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
    Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
    Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analyses of clinical trials in cancer: are they helpful to policy makers?
    Bennett CL; Armitage JL; LeSage S; Gulati SC; Armitage JO; Gorin NC
    Stem Cells; 1994 Jul; 12(4):424-9. PubMed ID: 7951008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.
    Schulman KA; Dorsainvil D; Yabroff KR; DiCesare J; Felser J; Eisenberg JM; Glick HA
    Bone Marrow Transplant; 1998 Mar; 21(6):607-14. PubMed ID: 9543065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM-CSF as an adjunct to autologous bone marrow transplantation.
    Gulati S; Bennett C; Phillips J; Van-Poznak C
    Stem Cells; 1993 Jan; 11(1):20-5. PubMed ID: 8457776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
    Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
    Stinson TJ; Adams JR; Bishop MR; Kruse S; Tarantolo S; Bennet CL
    Bone Marrow Transplant; 2000 Sep; 26(6):663-6. PubMed ID: 11041569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
    Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
    Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine therapy after bone marrow transplantation.
    Dix SP; Gilmore CE
    Pharmacotherapy; 1996; 16(4):593-608. PubMed ID: 8840365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic issues in the use of granulocyte-macrophage colony-stimulating factor for bone marrow transplantation or chemotherapy-induced neutropenia.
    Weber RJ
    Clin Ther; 1993; 15(1):180-91; discussion 168. PubMed ID: 8458047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?
    Bennett CL; Golub R; Waters TM; Tallman MS; Rowe JM
    Cancer Invest; 1997; 15(3):227-36. PubMed ID: 9171857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
    Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
    Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
    Colombat P; Delain M; Desbois I; Domenech J; Binet C; Tabah I; Lamagnere JP; Linassier C
    Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.